drug

Pipamperone

MeSH C005569
as of 2026-07-01
Add to landscapeMonitor thisCompare thisAsk about this
at a glance
small molecule
Pre-approval / investigational in the US
Developed by Hannover Medical School
2 trials in the graph
Synthesized from structured facts only — each point cited above.

Mechanism & identity

Modality
small molecule

Indications

Trials

2
Pharmacovigilance in Gerontopsychiatric Patients
NCT02374567Phase 3Terminated
POC Study of Pipamperone Added to Stable Treatment With RIS or PAL in Chronic Schizophrenia
NCT01450514Phase 2Completed

KOLs & investigators

2
Helge Frieling, Prof., MDKOL score 5
Marc L. Steinberg, PH.D.KOL score 5

Facts & assertions

0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
developer
Hannover Medical School
company
trial
Pharmacovigilance in Gerontopsychiatric Patients
PHASE3
trial
POC Study of Pipamperone Added to Stable Treatment With RIS or PAL in Chronic Schizophrenia
PHASE2
trial
indication
Schizophrenia
indication
Chronic Schizophrenia
indication
Depression
indication
Psychosomatic Disorders
indication
KOL
Helge Frieling, Prof., MD
KOL score 5
person
Marc L. Steinberg, PH.D.
KOL score 5
person